2021
Cutting Edge: Severe SARS-CoV-2 Infection in Humans Is Defined by a Shift in the Serum Lipidome, Resulting in Dysregulation of Eicosanoid Immune Mediators
Schwarz B, Sharma L, Roberts L, Peng X, Bermejo S, Leighton I, Casanovas-Massana A, Minasyan M, Farhadian S, Ko AI, Team Y, Dela Cruz CS, Bosio CM. Cutting Edge: Severe SARS-CoV-2 Infection in Humans Is Defined by a Shift in the Serum Lipidome, Resulting in Dysregulation of Eicosanoid Immune Mediators. The Journal Of Immunology 2021, 206: ji2001025. PMID: 33277388, PMCID: PMC7962598, DOI: 10.4049/jimmunol.2001025.Peer-Reviewed Original ResearchConceptsLipid mediatorsRisk factorsSevere diseaseSevere SARS-CoV-2 infectionHospitalized COVID-19 patientsSARS-CoV-2 infectionImportant immune regulatory roleSevere COVID-19COVID-19 patientsImmune regulatory roleProinflammatory lipid mediatorsCOVID-19Immunomodulatory eicosanoidsImmune mediatorsSerum lipidomeAdvanced agePatientsCOVID-19 pandemicCytochrome P450MortalityDiseaseDysregulationMediatorsLMS productsLipidome
2020
Identification of Potent and Safe Antiviral Therapeutic Candidates Against SARS-CoV-2
Xiao X, Wang C, Chang D, Wang Y, Dong X, Jiao T, Zhao Z, Ren L, Dela Cruz CS, Sharma L, Lei X, Wang J. Identification of Potent and Safe Antiviral Therapeutic Candidates Against SARS-CoV-2. Frontiers In Immunology 2020, 11: 586572. PMID: 33324406, PMCID: PMC7723961, DOI: 10.3389/fimmu.2020.586572.Peer-Reviewed Original ResearchConceptsSARS-CoV-2Therapeutic agentsAnti-coronaviral activitySARS-CoV-2 drugsWide therapeutic windowCOVID-19 infectionNovel therapeutic agentsEffective compoundsTherapeutic optionsReplication of coronavirusesSafe drugSevere diseaseTherapeutic windowHuman coronavirusesTherapeutic candidateUS FDAArbidol hydrochlorideIdentification of PotentTwo-step screenMillions of peopleSafety indexDrugsCOVID-19 pandemicFDACoronavirus